Bristol-Myers Squibb Initiates a Nationwide Voluntary Recall of COUMADIN® (warfarin sodium) Crystalline 5 mg Tablets, Lot Number 9H49374A
(Princeton, New Jersey, May 2, 2011) – Bristol-Myers Squibb Company (NYSE:BMY) initiated a voluntary recall of one lot of 1,000-count bottles of COUMADIN® (warfarin sodium) Crystalline 5 mg tablets. Bottles of 1,000 tablets are distributed to pharmacies for further dispensing to patients in prescription quantities. The lot number affected in the U.S. is 9H49374A with an expiry date of September 30, 2012. The recall is a precautionary measure based on the company’s testing of tablets from a returned bottle. A single tablet was found to be higher in potency than expected.
COUMADIN is prescribed to treat or prevent blood clots. A decrease of active ingredient may increase the risk of clots which could lead to heart attack or stroke and if there is too much active ingredient, there is an increased risk of bleeding.
Patients who may have 5 mg tablets should not interrupt their therapy but should seek advice from their pharmacist to see if they have tablets originating from the affected lot and if so, should consult their physician for appropriate medical advice.
Bristol-Myers Squibb is committed to ensuring patient safety and is working to resolve this issue quickly and appropriately. The company has notified the U.S. Food and Drug Administration (FDA), and will issue recall communications to all physicians and other customers involved.
Any adverse reactions may be reported to the FDA's MedWatch Program by fax at 1-800-FDA-0178, by mail at MedWatch, HF-2, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at www.fda.gov.
Healthcare professionals and customers may call the following for assistance if they have further questions about the recall:
| For information related to this recall: |
Stericycle, Inc.
1-866-918-8739 |
COUMADIN® (warfarin sodium) Prescribing Information (PDF: 172 KB)
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit www.bms.com.
Contacts
Media: Ken Dominski, 609-252-5251, ken.dominski@bms.com
Investors: John Elicker, 609-252-4611, john.elicker@bms.com